Soheil Meshinchi
About
Soheil Meshinchi is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Soheil Meshinchi has authored 328 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Hematology, 164 papers in Molecular Biology and 82 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Soheil Meshinchi's work include Acute Myeloid Leukemia Research (263 papers), Acute Lymphoblastic Leukemia research (82 papers) and Protein Degradation and Inhibitors (52 papers). Soheil Meshinchi is often cited by papers focused on Acute Myeloid Leukemia Research (263 papers), Acute Lymphoblastic Leukemia research (82 papers) and Protein Degradation and Inhibitors (52 papers). Soheil Meshinchi collaborates with scholars based in United States, Canada and South Africa. Soheil Meshinchi's co-authors include Todd A. Alonzo, Robert B. Gerbing, Jerald P. Radich, Derek L. Stirewalt, R.J. Arceci, Alan S. Gamis, Susana C. Raimondi, Ching‐Hon Pui, Betsy Hirsch and William L. Carroll and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.
In The Last Decade
Soheil Meshinchi
308 papers receiving 8.7k citations
Hit Papers
Peers
Soheil Meshinchi
Paresh Vyas United Kingdom
Mark J. Levis United States
Richard B. Lock Australia
Valeria Santini Italy
Kimberly Stegmaier United States
Beverly S. Mitchell United States
Carolyn A. Felix United States
Patrick Mayeux France
Andrew G. Hall United Kingdom
Fortunato Morabito Italy
Citations per year, relative to Soheil Meshinchi Soheil Meshinchi (= 1×)
peers
Paresh Vyas
Countries citing papers authored by Soheil Meshinchi
Since
Specialization
Citations
This map shows the geographic impact of Soheil Meshinchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soheil Meshinchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soheil Meshinchi more than expected).
Fields of papers citing papers by Soheil Meshinchi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Soheil Meshinchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soheil Meshinchi. The network helps show where Soheil Meshinchi may publish in the future.
Co-authorship network of co-authors of Soheil Meshinchi
This figure shows the co-authorship network connecting the top 25 collaborators of Soheil Meshinchi. A scholar is included among the top collaborators of Soheil Meshinchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soheil Meshinchi. Soheil Meshinchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pattwell, Siobhan S., et al.. (2023). Donor bone marrow–derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. Blood Advances. 7(19). 5851–5859.
2.
Choudhury, Samrat Roy, Jordan T. Bird, Stephanie D. Byrum, et al.. (2021). Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors. Blood. 138(Supplement 1). 2208–2208.
3.
Srivastava, Shivani, Jenny L. Smith, Amanda R. Leonti, et al.. (2021). Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical Cancer Research. 27(20). 5718–5730.
4.
Lamble, Adam J., Lisa Eidenschink Brodersen, Todd A. Alonzo, et al.. (2021). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 40(3). 252–261.
5.
Pollard, Jessica A., Erin Guest, Todd A. Alonzo, et al.. (2021). Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology. 39(28). 3149–3160.
6.
Tarlock, Katherine, Todd A. Alonzo, Yi-Cheng Wang, et al.. (2019). Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research. 25(16). 5038–5048.
7.
Hagiwara, Kohei, Liang Ding, Michael N. Edmonson, et al.. (2019). RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics. 36(5). 1382–1390.
8.
McNeil, Michael J., Marguerite T. Parisi, Nobuko Hijiya, et al.. (2018). Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. Journal of Pediatric Hematology/Oncology. 41(3). e174–e176.
9.
Meshinchi, Soheil, et al.. (2018). ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin. Blood. 132(Supplement 1). 1364–1364.
10.
Tarlock, Katherine, Todd A. Alonzo, Michael R. Loken, et al.. (2017). Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 23(14). 3649–3656.
11.
Brown, Fiona C., Paolo Cifani, Esther Drill, et al.. (2016). Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology. 176(1). 86–91.
12.
Farrar, Jason E., Rhonda E. Ries, Daniel Wai, et al.. (2016). Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research. 76(8). 2197–2205.
13.
Ostronoff, Fabiana, Megan Othus, Elihu H. Estey, et al.. (2015). Prognostic Significance of NPM1 Mutations in the Absence of FLT3 –Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. Journal of Clinical Oncology. 33(10). 1157–1164.
14.
Laszlo, George S., Todd A. Alonzo, Chelsea J. Gudgeon, et al.. (2015). Multimerin-1 ( MMRN1 ) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 21(14). 3187–3195.
15.
Tarlock, Katherine, Todd A. Alonzo, Robert B. Gerbing, et al.. (2015). Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3 /ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(8). 1951–1957.
16.
Dvinge, Heidi, Rhonda E. Ries, Janine O. Ilagan, et al.. (2014). Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proceedings of the National Academy of Sciences. 111(47). 16802–16807.
17.
Gamis, Alan S., Todd A. Alonzo, Soheil Meshinchi, et al.. (2014). Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology. 32(27). 3021–3032.
18.
Tarlock, Katherine, et al.. (2014). Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long‐term voriconazole. Pediatric Blood & Cancer. 62(5). 918–920.
19.
Alonzo, Todd A., Roland B. Walter, Robert B. Gerbing, et al.. (2013). Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy. Clinical Cancer Research. 19(6). 1620–1627.
20.
Ho, Phoenix A., Todd A. Alonzo, Robert B. Gerbing, et al.. (2013). High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. British Journal of Haematology. 162(5). 670–677.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paresh Vyas Breakdown of academic impact, for papers by Mark J. Levis Breakdown of academic impact, for papers by Richard B. Lock Breakdown of academic impact, for papers by Valeria Santini Breakdown of academic impact, for papers by Kimberly Stegmaier Breakdown of academic impact, for papers by Beverly S. Mitchell Breakdown of academic impact, for papers by Carolyn A. Felix Breakdown of academic impact, for papers by Patrick Mayeux Breakdown of academic impact, for papers by Andrew G. Hall Breakdown of academic impact, for papers by Fortunato Morabito